Literature DB >> 29150151

Evaluating short- and long-term impacts of a Medicaid "lock-in" program on opioid and benzodiazepine prescriptions dispensed to beneficiaries.

Rebecca B Naumann1, Stephen W Marshall2, Jennifer L Lund3, Nisha C Gottfredson4, Christopher L Ringwalt5, Asheley C Skinner6.   

Abstract

BACKGROUND: Insurance-based "lock-in" programs (LIPs) have become a popular strategy to address controlled substance (CS) (e.g., opioid) misuse. However, little is known about their impacts. We examined changes in CS dispensing to beneficiaries in the 12-month North Carolina Medicaid LIP.
METHODS: We analyzed Medicaid claims linked to Prescription Drug Monitoring Program (PDMP) records for beneficiaries enrolled in the LIP between October 2010 and September 2012 (n=2702). Outcomes of interest were 1) number of dispensed CS prescriptions and 2) morphine milligram equivalents (MMEs) of dispensed opioids while a) locked-in and b) in the year following release.
RESULTS: Compared to a period of stable CS dispensed prior to LIP enrollment, numbers of dispensed CS during lock-in and post-release were lower (count difference per person-month: -0.05 (95% CI: -0.11, 0.01); -0.23 (95% CI: -0.31, -0.15), respectively). However, beneficiaries' average daily MMEs of opioids were elevated during both lock-in and post-release (daily mean difference per person: 18.7 (95% CI: 13.9, 23.6); 11.1 (95% CI: 5.1, 17.1), respectively). Stratification by payer source revealed increases in using non-Medicaid (e.g., out-of-pocket) payment during lock-in that persisted following release.
CONCLUSION: While the LIP reduced the number of CS dispensed, the program was also associated with increased acquisition of CS prescriptions using non-Medicaid payment. Moreover, beneficiaries acquired greater dosages of dispensed opioids from both Medicaid and non-Medicaid payment sources during lock-in and post-release. Refining LIPs to increase beneficiary access to substance use disorder screening and treatment services and provider use of PDMPs may address important unintended consequences.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Controlled substance; Lock-in; Medicaid; Narcotic; Opioid; Prescription drug abuse

Mesh:

Substances:

Year:  2017        PMID: 29150151     DOI: 10.1016/j.drugalcdep.2017.10.001

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  6 in total

1.  Evaluation of a Medicaid Lock-in Program: Increased Use of Opioid Use Disorder Treatment but No Impact on Opioid Overdose Risk.

Authors:  Rebecca B Naumann; Andrew W Roberts; Stephen W Marshall; Asheley C Skinner
Journal:  Med Care       Date:  2019-03       Impact factor: 2.983

2.  Health Care Utilization and Comorbidity History of North Carolina Medicaid Beneficiaries in a Controlled Substance "Lock-in" Program.

Authors:  Rebecca B Naumann; Stephen W Marshall; Jennifer L Lund; Asheley C Skinner; Christopher Ringwalt; Nisha C Gottfredson
Journal:  N C Med J       Date:  2019 May-Jun

Review 3.  The Association of State Opioid Misuse Prevention Policies With Patient- and Provider-Related Outcomes: A Scoping Review.

Authors:  Amanda I Mauri; Tarlise N Townsend; Rebecca L Haffajee
Journal:  Milbank Q       Date:  2019-12-04       Impact factor: 4.911

4.  A Rapid Review of the Impact of Systems-Level Policies and Interventions on Population-Level Outcomes Related to the Opioid Epidemic, United States and Canada, 2014-2018.

Authors:  Bahareh Ansari; Katherine M Tote; Eli S Rosenberg; Erika G Martin
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

Review 5.  Connections Between Opioids and Road Injury: Linkage of Prescription Monitoring and Crash Databases.

Authors:  Rebecca B Naumann; Kristin Shiue; Amin Mohamadi Hezaveh; Stephen W Marshall; Christopher R Cherry
Journal:  Am J Prev Med       Date:  2019-12-19       Impact factor: 5.043

6.  Evidence for state, community and systems-level prevention strategies to address the opioid crisis.

Authors:  Tamara M Haegerich; Christopher M Jones; Pierre-Olivier Cote; Amber Robinson; Lindsey Ross
Journal:  Drug Alcohol Depend       Date:  2019-09-19       Impact factor: 4.852

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.